HC Wainwright Trims BriaCell Therapeutics (NASDAQ:BCTX) Target Price to $15.00

BriaCell Therapeutics (NASDAQ:BCTX) had its price target lowered by HC Wainwright from $18.00 to $15.00 in a research note published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ FY2029 earnings at ($0.05) EPS.

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $0.65 on Thursday. The firm has a market cap of $11.87 million, a P/E ratio of -0.52 and a beta of 1.31. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.36. The firm’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $1.53.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC grew its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,000 shares of the company’s stock after buying an additional 20,000 shares during the period. Onyx Bridge Wealth Group LLC owned approximately 0.31% of BriaCell Therapeutics worth $143,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.